Regulation FD Disclosure Form 8 K

The controlling stockholder and Co-Chairman of Pulse Biosciences, Inc. (the "Company"), Robert W. Duggan, has informed management that he is evaluating one or more potential market purchases of Company common stock, and the Company has cleared these pursuant to its Insider Trading Policy, giving Mr. Duggan through the end of December 10, 2024 to purchase, in his sole discretion, up to 500,000 shares of Company common stock.

The information contained in Item 7.01 to this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly stated otherwise.